WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
China's job market stableChina opens 829 sites providing free pneumoconiosis treatment'Ice city' sees booming tourism3 dead in east China residential complex fireInt'l travel expo kicks off in MacaoNative Youth Olympics: Alaska’s Indigenous teens emulate ancestors’ Arctic survival skillsThe Village Super League and the rural awakeningBeijing Central Axis: an exhibition of architectual beauty and a joy to behold at all timesMacao announces schedule for election of Chief Executive Election CommitteeChina opens 829 sites providing free pneumoconiosis treatment
2.2294s , 6502.4765625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,World Wave news portal